Guardian Pharmacy Reports Q3 Loss, Revenue Increases-August 2024-www.financetom.com

Guardian Pharmacy Reports Q3 Loss, Revenue Increases

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Guardian Pharmacy Reports Q3 Loss, Revenue Increases

Nov 13, 2024 2:22 AM

04:49 AM EST, 11/13/2024 (MT Newswires) -- Guardian Pharmacy Services ( GRDN ) reported a Q3 loss of $2 per share.

Two analysts polled by Capital IQ expected earnings of $0.22.

The company completed its initial public offering in September.

Revenue for the quarter ended Sept. 30 was $314.4 million, up from $262.7 million a year earlier.

Three analysts surveyed by Capital IQ expected $303.2 million.

For 2024, revenue is projected to be $1.21 billion to $1.22 billion. Three analysts surveyed by Capital IQ expect $1.19 billion.

Previous page： Hormel Foods Q1 Earnings: Organic Sales Edge Higher, EPS Misses, FY25 Outlook Intact And More Next page： Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Hormel Foods Q1 Earnings: Organic Sales Edge Higher, EPS Misses, FY25 Outlook Intact And More

Feb 27, 2025

Hormel Foods Corporation ( HRL ) shares are trading higher in the premarket session on Thursday. The company reported first-quarter adjusted earnings per share of 35 cents, missing the street view of 38 cents. Quarterly sales of $2.99 billion outpaced the analyst consensus estimate of $2.93 billion. Net sales fell 0.2% year over year, while organic sales rose by 1%....

Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines

Feb 27, 2025

Feb 27 (Reuters) - Novavax's ( NVAX ) fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 vaccines, its only product on the market. The company has struggled to keep up with the pace of its rivals Moderna ( MRNA ) and Pfizer ( PFE ), which make messenger RNA-based vaccines compared to its protein-based...

Tecnoglass Q4 Adjusted Net Income, Operating Revenue Rise; 2025 Revenue Guidance Set

Feb 27, 2025

08:06 AM EST, 02/27/2025 (MT Newswires) -- Tecnoglass ( TGLS ) reported Q4 adjusted net income Thursday of $1.05 per diluted share, up from $0.80 per share a year earlier. Four analysts polled by FactSet expected $1.02 per share. Operating revenue for the quarter ended Dec. 31 was $239.6 million up from $194.6 million a year earlier. Four analysts surveyed...

Payoneer Global Q4 Earnings Decrease; Revenue Increases; 2025 Outlook Issued

Feb 27, 2025

08:02 AM EST, 02/27/2025 (MT Newswires) -- Payoneer Global ( PAYO ) reported Q4 earnings Thursday of $0.05 per diluted share, down from $0.07 a year earlier. Analysts polled by FactSet expected $0.06. Revenue for the quarter ended Dec. 31 was $261.7 million, up from $224.3 million a year earlier. Analysts surveyed by FactSet expected $241.3 million. For 2025, the...